Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × betrixaban × Classical hematology × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Venous Thromboembolism 1

Interventions

Epoetin Alfa 26 Darbepoetin alfa 10 Dalteparin 8 Rivaroxaban 7 Cytarabine 7 Etoposide 6 apixaban 5 Idarubicin 5 Heparin, Low-Molecular-Weight 5 Daunorubicin 5 emicizumab 4 Tinzaparin 4 Thioguanine 4 Mitoxantrone 4 Methotrexate 4 Enoxaparin 4 Cyclophosphamide 4 pegfilgrastim 3 epoetin beta 3 Saline Solution 3 Radiotherapy 3 Hydrocortisone 3 Granulocyte Colony-Stimulating Factor 3 Erythropoietin 3 Dexamethasone 3 Aspirin 3 Asparaginase 3 oprelvekin 2 luspatercept 2 hetrombopag 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01583218 2023-08-07

APEX

Alexion Pharmaceuticals, Inc.

Phase 3 Completed

7,513 enrolled 18 charts 1 FDA

Classical hematology

Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡